|
|
|
|
|
SPONSORS
|
Conference Diamond Sponsor |
 |
|
Baxter through its subsidiaries assists healthcare professionals and their patients with treatment of complex medical conditions including hemophilia, immune disorders, kidney disease, cancer, trauma and other conditions. Baxter applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
Baxter is a leading manufacturer of plasma-based and recombinant proteins used to treat hemophilia. Other biopharmaceutical products include plasma-based therapies to treat immune disorders, alpha 1 antitrypsin deficiency and other chronic blood-related conditions; biosurgery products for hemostasis, wound-sealing, and tissue regeneration; and vaccines.
In 2006 Baxter has launched Kiovig, a plasma-based product used to bolster the immune systems of people with immune deficiencies. The product offers fast and effective treatment and enhanced convenience. Its efficacy and tolerability have been demonstrated in multi-center clinical trials in Europe and the United States. The manufacturing process also incorporates three dedicated viral reduction steps. The ready-to-use preparation eliminates the need for reconstitution and its 10% concentration allows for reduced infusion volume when compared to 5% concentrations. In addition, it is the first and only 10% IVIG solution with the following combination of features: no added sugars, no added sodium, no added preservatives, latex-free packaging and an option to store the product at room temperature for up to nine months. Kiovig is Baxter’s latest step in its ongoing efforts to advance the science of intravenous immunoglobulin (IVIG) therapy.
Baxter works hand in hand with physicians, nurses and patients to advance therapies and access to care and is delighted to support the EU consensus conference for primary immune deficiencies.
In addition to their Diamond Sponsorship of the EU PID Consensus Conference, IPOPI wish to thank Baxter for their on-going support for this project. This has been in the form of in-kind logistical advice for the conference set up and subsequent dissemination of the conference results.
>> http://www.immunedisease.com |
|
Dinner and Accommodation Diamond Sponsor |
 |
|
Talecris Biotherapeutics discovers, develops, and delivers life-saving and life-enhancing protein therapies to markets throughout the world. Through our distinct focus on product development, state-of-the-art manufacturing processes, and strong commitment to customer service, Talecris is building upon a 60-year legacy of innovation to raise patient care to a level not seen before.
Talecris Biotherapeutics offers a portfolio of innovative protein therapies and complementary programs and services. Our products include:
- Gamunex® (Immune Globulin Intravenous {Human}, 10%
- Caprylate/Chromatography Purified)
- Prolastin® (Alpha1-Proteinase Inhibitor {Human}
- Koate®– DVI (Antihemophilic Factor {Human})
- Plasbumin® (Albumin {Human})
- Thrombate® III (Antithrombin III {Human})
- Hypermune™ line
Talecris employs 1900 talented professionals and leading scientists committed to making a difference in the lives of patients and the health care communities we serve. We continue to invest significantly in our business to establish new standards of care and to expand our presence globally, with a goal of satisfying our growing patient needs. Through a focused entrepreneurial approach that builds on our strong history of industry firsts, Talecris will continue providing therapeutic protein products and services to advance care now and into the future.
Providing life-saving and life-sustaining protein therapeutics.
>> http://www.talecris.com |
|
Platinum Sponsor |
 |
|
ZLB Behring is one of the world’s leading pharmaceutical companies specializing in the manufacture of plasma products. Its comprehensive line of therapies include products for the treatment of hemophilia and other coagulation disorders, immunoglobulins for the prevention and treatment of immune disorders, treatments that inhibit the formation of blood clots, wound-healing agents used during major surgical procedures, and plasma expanders for the treatment of a variety of conditions such as shock, burns and circulatory disorders. Additionally, ZLB Behring operates one of the world’s largest, fully-owned plasma collection networks.
ZLB Behring is committed to developing the next generation of therapeutic proteins to meet the demands of the evolving market. Products under development include subcutaneous immunoglobulin treatment for primary immune deficiency and fibrin dressings for use in cases of severe hemorrhage.
At plants located in Bern, Switzerland; Marburg, Germany; and Kankakee, Illinois, ZLB Behring manufactures therapies in accordance with international safety and quality standards. The products are distributed worldwide.
ZLB Behring is a subsidiary of CSL Limited, a pharmaceutical company which operates worldwide from headquarters in Melbourne, Australia.
>> http://www.zlbbehring.com |
|
Premium Sponsor |
 |
|
Octapharma, a biopharmaceutical company, was founded in 1983. Our mission is to work for the safe and optimal usage of human plasma. Our products are state-of-the-art within treatment of haemophilia, immune diseases, volume expansion and plasma transfusions. Octapharma is a privately held company with it’s headquarters located in Lachen, Switzerland. Manufacturing pants are situated in Vienna, Austria, Lingolsheim, France, and Stockholm, Sweden, with a fine fractionation plant in Mexico. Our sales subsidiaries are located in most European countries, as well as in North and South America and Australia. Apart from the sale of finished products, Octapharma has been in the forefront with assisting countries in establishing self-sufficiency projects through licensing of Octapharma's technology or through manufacturing agreements.
It is Octapharma’s aim to stay at the forefront of Research & Development of new plasma products and our human cell-based recombinant factor VIII, as well as maintaining manufacturing excellence for the benefit of the patient.
In addition to their premium sponsorship of the EU PID Consensus Conference, IPOPI wish to thank Octapharma for their support to help disseminate the results of the conference. This has been in the form of a grant that has enabled IPOPI to place an advertorial in the 2006 October edition of the EU Parliament Magazine.
|
|
Classic Sponsor |
 |
|
People: what matters most
Our one main objective is to develop services and products designed to secure the health and well-being of humanity. Grifols products reach countless patients, physicians and hospitals in over 70 countries around the world. Specialized in the health and pharmaceutical sector, Grifols researches, develops, manufactures and markets plasma derivatives, I.V. therapy products, clinical nutrition, reagents, clinical diagnostic instruments and medical materials. The company’s manufacturing plants are located in Los Angeles, USA and in Barcelona, Spain.
Grifols has been working for health since 1940 creating innovative products and services based on the values of ethics and responsibility.
Grifols has created three divisions to offer specialized products and services grouped according to the distinctive needs we serve: Bioscience Division, Diagnostic Division and Hospital Division. Several of these products and services of the different divisions enable us to maintain specific synergies and offer the healthcare professional a global approach to many diseases, from diagnosis to therapy.
. Bioscience Div: specializes in the development of high quality plasma-derived therapies with outstanding records of safety and efficacy. These products are Grifols’ original and principal product line, currently now registered in over 50 countries worldwide. Grifols´ plasma derivatives portfolio includes an intravenous immunoglobulin leading such kind of therapy in Europe and having received an excellent acceptance on its recent introduction in USA.
. Diagnostic Div: advanced diagnostic products for laboratory analysis, Hospital Blood Banks and Transfusion Centers.
. Hospital Div: diverse products for the hospital pharmacy, surgery, nutritional support, fluid therapy and many more.
>> http://www.grifols.com |
|
Classic Sponsor |
 |
|
LFB (French laboratory for blood fractionation and biotechnologies) is a one of Europe’s leading laboratories in the field of plasma-derived medicinal products. As a French State-owned company, LFB’s ethical commitment and public health mission are reflected in a broad range of medicinal products that benefit from the highest quality and safety standards.
Some of our products, like polyclonal immunoglobulins (TEGELINE®), are essential for the treatment of patients with rare, serious or incapacitating diseases, including primary immunodeficiency, secondary immunodeficiency and auto-immune diseases.
(www.lfb.fr).
LFB has supported since its creation IRIS, the French association of hereditary immunodeficiency patients, and its role of informing and raising awareness among families and the medical profession.
(www.associationiris.org)
|
|
|
|
|
|